Level 1 — Absolute Beginner
Pancreatic cancer is a very serious illness. Most patients do not live long after they get this cancer. Doctors around the world are trying to find better treatments.
A new medicine called daraxonrasib is showing good results. In a big study, patients who took this medicine lived much longer. Patients lived about 13 months. Patients who took the old medicine lived only about 7 months.
Scientists and doctors are very excited about this news. The medicine could help many people in the future. It is still being studied before it can be given to all patients.
- cancer
- a serious disease where cells in the body grow out of control
- medicine
- a substance taken to treat or prevent illness
- treatment
- a way of helping a sick person get better
- patient
- a person who receives medical care
- study
- careful research done to find new information
- survive
- to continue to live after a difficult event
- result
- the outcome or effect of an action or experiment
- scientist
- a person who studies science and does research
Level 2 — Elementary
A new drug called daraxonrasib has shown very promising results in treating pancreatic cancer. This cancer is one of the most deadly, and patients often survive less than a year after diagnosis. Scientists presented the results at the ASCO 2026 cancer conference in Chicago.
In the clinical trial, 500 patients with advanced pancreatic cancer were studied. Patients who received daraxonrasib lived a median of 13.2 months. Patients who received standard chemotherapy lived only 6.7 months. This means the new drug reduced the risk of death by 60 percent.
Daraxonrasib is taken as a pill. It targets a gene called RAS, which is found in many cancer cells. The drug's maker, Revolution Medicines, plans to apply to the FDA for approval. Doctors at the conference gave the results a 42-second standing ovation.
- clinical trial
- a scientific test of a new medical treatment on people
- median
- the middle value in a set of numbers
- chemotherapy
- treatment using powerful drugs to destroy cancer cells
- gene
- a section of DNA that controls how the body works
- standing ovation
- when an audience stands up to clap enthusiastically
- approval
- official permission from a government agency for a drug to be sold
- advanced
- at a late or serious stage of a disease
- diagnosis
- the identification of an illness by a doctor
Level 3 — Intermediate
At the ASCO 2026 Plenary Session in Chicago, Revolution Medicines presented the results of the RASolute 302 Phase 3 trial for daraxonrasib, an oral RAS multiselective inhibitor targeting metastatic pancreatic ductal adenocarcinoma in patients with previously treated disease. The results drew what many observers described as one of the most emotionally charged moments in oncology conference history: a 42-second standing ovation from thousands of cancer specialists.
The trial enrolled 500 patients and compared daraxonrasib against physician's choice of chemotherapy. The primary endpoint, median overall survival, was 13.2 months for daraxonrasib versus 6.7 months for chemotherapy, representing a 60 percent reduction in risk of death (HR 0.40; P less than 0.0001). Unlike earlier RAS inhibitors such as sotorasib and adagrasib, which target only the KRAS G12C mutation, daraxonrasib works across all RAS variants, covering about 90 percent of pancreatic cancer patients who carry RAS mutations.
The results were simultaneously published in the New England Journal of Medicine and were co-authored by Dr. Brian Wolpin of Dana-Farber Cancer Institute. The FDA has granted daraxonrasib both Breakthrough Therapy Designation and Orphan Drug Designation. Revolution Medicines intends to file a Biologics License Application before the end of 2026. The drug represents the first meaningful advancement in a disease where RAS was considered essentially undruggable for decades.
- oncology
- the branch of medicine that studies and treats cancer
- ductal adenocarcinoma
- the most common type of pancreatic cancer, starting in the duct cells
- multiselective inhibitor
- a drug that blocks multiple related targets simultaneously
- primary endpoint
- the main result a clinical trial is designed to measure
- hazard ratio
- a statistical measure comparing the rate of events between two groups (HR)
- mutation
- a change in a gene that may affect how cells grow or function
- Breakthrough Therapy Designation
- an FDA status that speeds up the development of drugs for serious conditions
- undruggable
- a target in the body previously thought impossible to treat with drugs
Level 4 — Advanced
The ASCO 2026 Plenary Session in Chicago became the setting for what clinical oncologists are already describing as a watershed moment in gastrointestinal oncology, as Revolution Medicines presented the RASolute 302 Phase 3 data for daraxonrasib in previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). The audience of several thousand oncologists, many of whom have spent careers delivering sentences of months to PDAC patients, responded with a 42-second standing ovation, a reaction more commonly associated with political rallies than scientific conferences.
The mechanism underlying daraxonrasib's efficacy distinguishes it categorically from earlier entries in the KRAS-inhibition space. While sotorasib and adagrasib achieved regulatory approval by selectively targeting the KRAS G12C mutation, which is present in only 1-3 percent of PDAC patients, daraxonrasib operates as a RAS(ON) multiselective inhibitor that suppresses all oncogenic RAS variants in their active, GTP-bound conformation. This broader targeting envelope encompasses approximately 90 percent of PDAC patients, who carry activating mutations in KRAS, NRAS, or HRAS. The RASolute 302 trial randomized 500 patients 1:1 to daraxonrasib or physician's choice chemotherapy; the primary endpoint of median overall survival was 13.2 months versus 6.7 months (HR 0.40; 95% CI 0.32-0.50; P less than 0.0001), representing a 60 percent reduction in the hazard of death.
The results were simultaneously published in the New England Journal of Medicine and co-authored by Dana-Farber Cancer Institute's Dr. Brian Wolpin. The FDA had previously granted daraxonrasib Breakthrough Therapy Designation and Orphan Drug Designation, both of which are expected to expedite the review timeline after Revolution Medicines submits its New Drug Application before the close of 2026. The clinical significance extends beyond PDAC: RAS mutations are present in approximately 30 percent of all human cancers, and the platform technology underlying daraxonrasib is already being evaluated in non-small cell lung cancer and colorectal adenocarcinoma, potentially heralding a new era in pan-RAS oncology.
- watershed
- a turning point that marks a significant change in a field or situation
- gastrointestinal
- relating to the stomach and intestines
- GTP-bound conformation
- the active shape of a RAS protein when bound to GTP, driving cell growth signaling
- oncogenic
- having the potential to cause cancer
- targeting envelope
- the range of molecular targets a drug can act on
- hazard of death
- the statistical rate at which patients in a trial are dying
- pan-RAS
- describing drugs or approaches that work across all RAS protein variants
- heralding
- announcing or signalling the approach of something important
